samedan logo
 
 
 
spacer
home > ebr > spring 2003 > variant creutzfeldt-jakob disease: safety of blood and plasma products
PUBLICATIONS
European Biopharmaceutical Review

Variant Creutzfeldt-Jakob Disease: Safety of Blood and Plasma Products

Transmissible spongiform encephalopathies (TSEs) are rare but invariably fatal neurodegenerative disorders affecting both animals and humans. The infectious agent is a modified form of a naturally occurring protein, composed largely of a self-replicating protein referred to as a prion.

In 1996 a new variant of Creutzfeldt-Jakob disease (vCJD) was described in Great Britain. Cases of vCJD are very rare and have occurred primarily in Great Britain. According to the British Department of Health, as of 6th January 2003 the number of probable or confirmed cases of vCJD in the UK had risen to 129. In addition, there have been six cases in France, one in the Republic of Ireland and one in Italy as well as one in the US. (This last case had been a resident in the UK but it is regarded as a US case. This is because cases are normally assigned to the country of residence at the time of onset of symptoms.)


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Sonja Lenz, Study Director, Klaus Kellings, Business Development Regional Manager, and Helga Siakkou, Quality Control Manager, at NewLab BioQuality AG

Sonja Lenz has been Study Director for prion studies at NewLab BioQuality AG since 2001. She studied Chemical Engineering at the Niederrhein University of Applied Sciences in Krefeld, and at NewLab she was responsible for establishing and validating the Western blots used in these studies.

Sonja has also performed several GLP-compliant studies whose results have been presented at various international meetings.

Dr Klaus Kellings works in the Business Development department at NewLab BioQuality AG. Prior to this position, he acted as Study Director for Virology at NewLab, responsible for viral and prion process validation studies. He gained experience in prion research during his studies in Biophysics at the University of Dьsseldorf and his post-doctoral research at the University of California in San Francisco. This experience has been invaluable in establishing the prion techniques used at NewLab.

Dr Helga Siakkou is currently Quality Control Manager at NewLab. She obtained her degree in Biochemistry at the State University of Kharkov, Ukraine, and a PhD in Molecular Biology and Virology from the Academy of Sciences in Berlin, Germany. Her research interests lie primarily in the area of retrovirus research. Helga has worked at NewLab BioQuality AG since 1994.
spacer
Sonja Lenz
spacer
spacer
spacer
Dr Klaus Kellings
spacer
spacer
spacer
Dr Helga Siakkou
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Leading pharma packaging companies commit to supply for Covid-19 fight

The CEOs of Gerresheimer, Stevanato Group, and SCHOTT are committed to ensuring ample supply of pharmaceutical containers for any Covid-19 vaccine and treatment that is developed, and that no patient shall be left behind, no matter what region of the world they live in. Also, the companies will make every effort to support the pharma industry’s’ priorities for overall medication supply in addition to Covid-19 drugs. Each of the three companies manufactures billions of type-1 borosilicate glass vials, the most proven and most widely available material used to store and deliver vaccines around the world. They are making the statement to provide confidence in the global pharmaceutical supply chain in times of uncertainty.
More info >>

White Papers

Migration safe pharmaceutical labels improve patient safety

UPM Raflatac

Labels play an invaluable role on pharmaceutical packages. Pharmaceutical companies should only use labels that meet low-leachability and extraction requirements. Labels that are not migration safe, e.g. create leachable chemical compounds, may fail testing and result in significant launch delays or costly recalls. This white paper presents how pharmaceutical companies can ensure that the final label constructions achieve their business, regulatory and patient safety goals.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement